Cover Image
市場調查報告書

心臟標記

Cardiac Markers

出版商 Kalorama Information 商品編碼 360876
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
心臟標記 Cardiac Markers
出版日期: 2016年06月16日 內容資訊: 英文 71 Pages
簡介

本報告以心臟標記市場為焦點,提供心臟標記市場評估,使用生物標記的心臟疾病 (CVD) 檢驗的估計、競爭分析,全球心血管疾病生物標記診斷市場預測,心臟疾病的主要的IVD標記,心臟疾病的主要生物標記、生物標記面板與其開發/銷售企業,主要的脂質生物標記與其開發/銷售企業等系統性資訊。

第1章 摘要整理

第2章 簡介

第3章 市場分析

第4章 企業簡介

  • Abbott Laboratories
  • ALPCO
  • ARUP Laboratories
  • Axis-Shield Diagnostics, Ltd. (Alere Company)
  • Beckman Coulter, Inc. (Danaher Corporation 子公司)
  • bioMerieux SA
  • CardioDx, Inc.
  • CardioGenics Holdings Inc.
  • Gamma Therapeutics, Inc.
  • Ortho-Clinical Diagnostics
  • Quest Diagnostics
  • Randox Laboratories Ltd.
  • RENESE UG
  • Roche
  • Tosoh
  • Tosoh生物科學產業部

圖表

目錄
Product Code: KLI15030206

Biomarkers are biological or biochemical molecules, or genetic changes, or other characteristics that can be measured, and that indicate or predict a condition, risk, or likely response. Biomarkers can be used for a range of diagnostic applications including predicting disease risk, diagnosis, predicting prognosis, identifying appropriate therapy for an individual, monitoring disease or for return of a disease, and other applications. With the incidence of cardiovascular disease increasing greatly, cardiac markers and cardiovascular biomarkers are in huge demand. Cardiac Markers provides market assessment, estimate and competitive analysis for tests for cardiovascular disease (CVD) that use biomarkers, including:

  • Worldwide Cardiovascular Disease Biomarkers Diagnostic Market - 2015 and 2020
  • Selected IVD Markers of Cardiovascular Disease
  • Selected Biomarkers and Biomarker Panels for Cardiovascular Disease, and Companies Developing/Marketing These Biomarkers
  • Selected Lipid Biomarkers, and Companies Developing/Marketing These Biomarkers

Physicians use cardiac markers (CK-MB, troponin I, troponin T, myoglobin, brain natriuretic peptide (BNP), proBNP, high sensitive C-reactive protein (hsCRP), and homocysteine) and cardiovascular biomarkers in two ways: acute care to diagnose a cardiac event in a hospital emergency room (acute care) or chronic care to evaluate the risk of a cardiovascular event occurring and to monitor patients with a cardiovascular disease. The traditional markers - CK-MB, troponin and myoglobin - were used in acute care and tests such as cholesterol were used to evaluate risk.

In the past few years cardiac markers have been revitalized with tests such as myeloperoxidase (MPO) brain natriuretic peptide (BNP), proBNP becoming part of the acute care test menu and tests such as high sensitive C-reactive protein (hsCRP), high sensitive troponin, homocysteine, Fatty Acid Binding Protein (FABP), Glycogen Phosphorylase isoenzyme BB (GPBB), urinary albumin, S-100 protein and hemoglobin A1c (hbA1c) now part of the risk evaluation tool box.

Cardiac Markers reviews the progression of cardiac diagnostic technologies and notes some trends in test strategies as well, including:

  • Cardiac Risk
  • Genetics and Cardiovascular Disease
  • Acute Myocardial Infarction and Acute Coronary Syndrome
  • Heart Failure
  • Lipid Disorders
  • ACP Coronary Heart Disease Screening

As diagnostic companies strive to provide platforms allowing for quick yet accurate diagnoses of patients, there is growing opportunity in the cardiac marker market. In the U.S., the Affordable Care Act (ACA), which is designed to advance healthcare accessibility, has helped to drive the market. The ACA encourages a shift toward payment based on the value of care.

There are currently a number of companies developing or marketing cardiac markers and cardiovascular biomarkers. This report contains profiles of many of the top competitors, including:

  • Abbott Laboratories
  • American Laboratory Products Company (ALPCO)
  • ARUP Laboratories
  • Axis-Shield Diagnostics, Ltd. (An Alere Company)
  • Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
  • bioMérieux SA
  • CardioDx, Inc.
  • CardioGenics Holdings, Inc.
  • Diagenics International Corporation
  • Gamma Therapeutics, Inc.
  • Quest Diagnostics
  • Ortho-Clinical Diagnostics
  • Randox Laboratories Ltd.
  • RENESE UG
  • Roche Diagnostics
  • Siemens Healthcare Diagnostics
  • Tosoh Corporation / Tosoh Bioscience, Inc.

The information presented in this report is derived on publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and interviews with industry professionals and experts in the areas of in vitro diagnostics and personalized medicine.

Table of Contents

ONE: EXECUTIVE SUMMARY

TWO: INTRODUCTION

  • Overview
  • Cardiac Risk
  • Genetics and Cardiovascular Disease
  • Acute Myocardial Infarction and Acute Coronary Syndrome
  • Heart Failure
  • Lipid Disorders
  • ACP Coronary Heart Disease Screening

THREE: MARKET ANALYSIS

FOUR: COMPANY PROFILES

  • Abbott Laboratories
    • Recent Revenue History
    • Company Overview - Focusing on Biomarkers
  • ALPCO
  • ARUP Laboratories
    • Recent Revenue History
    • Company Overview
  • Axis-Shield Diagnostics, Ltd. (An Alere Company)
    • Recent Revenue History
    • Company Overview
  • Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
    • Recent Revenue History
    • Company Overview
  • bioMérieux SA
    • Recent Revenue History
    • Company Overview
  • CardioDx, Inc.
  • CardioGenics Holdings Inc.
  • Gamma Therapeutics, Inc.
  • Ortho-Clinical Diagnostics
    • Recent Revenue History
    • Company Overview
  • Quest Diagnostics
    • Recent Revenue History
    • Cardiovascular Testing
  • Oncology
  • Toxicology
  • Randox Laboratories Ltd.
    • Recent Revenue History
    • Company Overview
  • RENESE UG
  • Roche
    • Recent Revenue History
    • Company Overview
    • Recent Revenue History
    • Company Overview
  • Tosoh Corporation
  • Tosoh Bioscience, Inc.
    • Recent Revenue History
    • Company Overview

LIST OF EXHIBITS

TWO: INTRODUCTION

  • Table 2-1: Selected IVD Markers of Cardiovascular Disease (CVD)
  • Table 2-2: Selected Biomarkers and Biomarker Panels for Cardiovascular Disease, and Companies Developing/Marketing These Biomarkers
  • Table 2-3: Selected Lipid Biomarkers, and Companies Developing/Marketing These Biomarkers

THREE: MARKET ANALYSIS

  • Table 3-1: Worldwide Cardiovascular Disease Biomarkers Diagnostic Market -2015 and 2020
Back to Top